Actively Recruiting
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Led by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Updated on 2026-02-03
600
Participants Needed
1
Research Sites
751 weeks
Total Duration
On this page
Sponsors
T
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Lead Sponsor
O
Okayama University
Collaborating Sponsor
AI-Summary
What this Trial Is About
To determine the incidence and risk factors in the development of ovarian, fallopian tube, and peritoneal cancers in Japanese women carrying Breast Cancer Susceptibility Gene (BRCA)1/2 variants.
CONDITIONS
Official Title
Prospective Cohort Study of Germline Variant Carriers With BRCA1 or BRCA2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women carrying BRCA1 or BRCA2 gene variants, including variants of uncertain significance
- Women who have received genetic counseling at a medical institution before joining the study
- Women aged 20 years or older
- Women who provide written consent to participate
You will not qualify if you...
- Women who have ovarian or fallopian tube cancer at the time of giving consent
- Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer
- Women considered unsuitable for the study by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Okayama University
Okayama, Japan
Actively Recruiting
Research Team
A
Akira Hirasawa, M.D., Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here